Sorry, we can’t find the page you were looking for…

Here are some helpful links to get you where you need to be…

Deallus Homepage

Deallus is a unique strategic intelligence consultancy operating across the global life sciences sector

About

We offer a broad range of career opportunities, dependent on your life sciences experience

Available roles

We have a number of global offices and we’re ready and waiting to talk about how we can assist you with your project

Get in touch

We are a company of experienced and dedicated life sciences specialists. Our unparalleled competitive intelligence capabilities are enhanced by the strategic mindset that drives our entire organization.

This enables us to provide you with the assured guidance you need to make the right strategic decisions. We are well equipped to assist with any issue at any stage of your product’s lifecycle.

Our Capabilities
Deallus Strategic Intelligence Services
Therapeutic Area Strategy Development Brand StrategyDevelopment Brand Planning Brand Positioning Product Launch Benchmarking Pricing &Reimbursement Competitive Deep Dives Commercial Competitive Analysis Competitor Threat Analysis Workshops Conference Coverage Scenario Planning & War Gaming C.I. Best Practice Advisory

Therapeutic Area Strategy Development

  • Clinical pathway design
  • Trial design
  • BD&L/Partnering Strategy
  • Portfolio prioritization

Brand Strategy Development

  • Forecasting
  • Stakeholder selection & engagement
  • Market Research
  • Message development
  • Patient journey

Brand Planning

  • Strategic/tactical plan development
  • Forecasting
  • Budgeting & tactics
  • Customer segmentation
  • Brand planning process support/PMO

Brand Positioning

  • Brand attribute testing
  • Differentiation
  • Positioning research
  • Training plan

Product Launch

  • Launch plan development
  • Launch office set-up & day-to-day operation
  • Launch readiness assessment
  • Progress reviews & tracking

Benchmarking

  • Analogue analysis
  • Best practices
  • Key performance drivers
  • Competitive capabilities

Pricing & Reimbursement

  • Payer landscape assessment
  • Pricing strategy
  • Patient support
  • Contracting strategy
  • Payer segmentation

Competitive Deep Dives

Competitive profiling of multiple potential sources of competitive advantage
  • TPP
  • Commercial capabilities
  • Regulatory/government affairs set-up
  • Pricing reimbursement approach
  • Value-added services
  • Field stakeholder engagement

Commercial Competitive Analysis

Studies on competitors:
  • Sales teams
  • Account teams
  • Commercial digital approach
  • Product positioning/messaging

Competitor Threat Analysis

Detailing competitor:
  • Strengths & weaknesses
  • Decision-making timelines
  • Commitments
  • Strategic intent

Workshops

  • Alignment workshops
  • Discovery workshops
  • Competitive insights workshops

Conference Coverage

  • In-depth coverage of presentations & booth displays
  • Expert commentary at industry conferences worldwide

Scenario Planning & War Gaming

  • Role plays
  • Simulations
  • What-if/contingency planning
  • Communications roadmap building

C.I. Best Practice Advisory

  • Boot camps
  • Masterclasses
  • Organization design for world-class C.I. functions

National Healthcare Security Administration (NHSA) protocols

Categories: News|Tags: |

On 4 July 2023, the National Healthcare Security Administration (NHSA) published the drafted 'Protocol for Renewal of NRDL Listed Drugs’ and ‘Negotiation Rules for Non-Exclusive Drug’. The two protocols aim to streamline the negotiation process for NRDL listed drugs and those with generic versions and are eligible for NRDL listing.

China Pharma Market Access (CPMA)

Categories: News, White Paper|Tags: |

Since the establishment of the China National Medical Insurance Bureau in 2018, the goal has been to strengthen public health and medical service levels, achieve maximum utilisation of the national medical insurance fund, and to enhance the strategic purchasing capability of medical insurance funds. Significant tools in achieving this are the National Reimbursement Drug List (NRDL) and drug Volume Based Procurement (VBP), which have opened a new chapter in China’s medical reform. Meanwhile, the new drug registration process is improved, simplified, and accelerated.

Go to Top